The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

In the treatment of pancreatic ductal adenocarcinoma (PDAC), comorbidities such as cachexia limit quality of life and survival. Here, the authors show TLR7/8 agonist R848 remodels host and tumour immune responses, promoting survival and attenuating cachexia in murine models of PDAC.

Bibliographic Details
Main Authors: Katherine A. Michaelis, Mason A. Norgard, Xinxia Zhu, Peter R. Levasseur, Shamilene Sivagnanam, Shannon M. Liudahl, Kevin G. Burfeind, Brennan Olson, Katherine R. Pelz, Diana M. Angeles Ramos, H. Carlo Maurer, Kenneth P. Olive, Lisa M. Coussens, Terry K. Morgan, Daniel L. Marks
Format: Article
Language:English
Published: Nature Publishing Group 2019-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-12657-w

Internet

https://doi.org/10.1038/s41467-019-12657-w

Similar Items